A randomized controlled trial of a therapeutic relational agent for reducing substance misuse during the COVID-19 pandemic
Judith J. Prochaska(Stanford University), Athena Robinson(Cabot (United States)), Kenneth R. Weingardt(Northwestern University), Michael Baiocchi(Stanford University), Alison Darcy(Wolters Kluwer Health), Sarah Pajarito(Wolters Kluwer Health), Dale Dagar Maglalang(Stanford University), Amy Chieng(Stanford University), Erin A. Vogel(Stanford University)
Cited by 92
Related Papers
Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies
|Circulation|2013|407
IntelliCare: An Eclectic, Skills-Based App Suite for the Treatment of Depression and Anxiety
|Journal of Medical Internet Research|2017|333
A Therapeutic Relational Agent for Reducing Problematic Substance Use (Woebot): Development and Usability Study
|Journal of Medical Internet Research|2021|257
Evidence of Human-Level Bonds Established With a Digital Conversational Agent: Cross-sectional, Retrospective Observational Study
|JMIR Formative Research|2021|220
What variables are associated with successful weight loss outcomes for bariatric surgery after 1 year?
|Surgery for Obesity and Related Diseases|2014|100